Nature Reviews Drug Discovery | CountryOfPapers
Volume 15 | Nature Reviews Drug Discovery
Volume 20 Issue 2, February 2021
Volume 20 Issue 11, November 2021
Can the pharmaceutical industry reduce attrition rates? | Nature Reviews Drug Discovery
PAASP publication in Nature Reviews Drug Discovery: Improving target assessment in biomedical research - the GOT-IT recommendations - paasp network
Screening out irrelevant cell-based models of disease | Nature Reviews Drug Discovery
The future of drug development: advancing clinical trial design | Nature Reviews Drug Discovery
Volume 19 Issue 6, June 2020
Volume 14 | Nature Reviews Drug Discovery
Volume 20 Issue 4, April 2021
Predicting in vivo drug interactions from in vitro drug discovery data | Nature Reviews Drug Discovery
Volume 18 Issue 6, June 2019
Pharmacogenetics in drug discovery and development: a translational perspective | Nature Reviews Drug Discovery
The druggable genome | Nature Reviews Drug Discovery
Target deconvolution strategies in drug discovery | Nature Reviews Drug Discovery
Volume 3 | Nature Reviews Drug Discovery
Volume 13 | Nature Reviews Drug Discovery
Nature Reviews Drug Discovery - Wikipedia
Volume 19 Issue 11, November 2020
Volume 21 Issue 3, March 2022
Article series : Nature Reviews Drug Discovery
Phase II and Phase III attrition rates 2011–2012 | Nature Reviews Drug Discovery
Zebrafish as tools for drug discovery | Nature Reviews Drug Discovery
Nature Reviews - Nature Reviews Drug Discovery: Invasive fungal infections are a major medical concern, particularly in immunocompromised patients. In this Review, Perfect discusses the antifungal pipeline, including advances in the currently
